A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

This article provides a descriptive account of the reports from the literature regarding the use of a combination of dexmedetomidine and ketamine for procedural sedation. Data Source: A ...

According to the United States Drug Enforcement Administration (DEA), ketamine is a “dissociative anesthetic that has some hallucinogenic effects” and “can induce a state of sedation ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Side effects seen with IV and intranasal ketamine like dissociation, sedation, and increased blood pressure were also minimal, with the most common adverse reactions including dizziness and headache.

Start your Independent Premium subscription today. Ketamine was previously reclassified from class C to class B in 2014, and since then, the number of users has continued to rise. The most recent ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available ... Because of the risks for sedation, dissociation, abuse and misuse, it is only available at health care settings that ...

Spravato is made from esketamine, one of two mirror-image molecules found in the anesthetic ketamine. It was approved in 2019 ...

In this edition of “Rising High,” The Fly conducted an exclusive interview with Erez Aminov, Chairman & Chief Executive Officer of MIRA ...

Koruk et al 17 Prospective randomized trial comparing dexmedetomidine–ketamine with midazolam-ketamine in 50 pediatric patients for extracorporeal shock wave lithotripsy Sedation was equally ...